- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. ALK may be activated in cancer through multiple mechanisms. The most common mechanism is through formation of a fusion protein from chromosomal translocations, as in the case of anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors. ALK may also be amplified through mutation, as in neuroblastomas. Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express ALK. ALK staining is present within both the nucleus and cytoplasm, and are positive in about 60% of ALCL. ALK protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome.
For additional ALK and oncogenic kinase research antibodies targeting fusion protein signaling, lung cancer biomarkers, and lymphoma-associated receptor tyrosine kinase pathways, explore the broader ALK Antibody page featuring recombinant rabbit monoclonal clone ALK1/6698R.
Optimal dilution of the recombinant Anaplastic Lymphoma Kinase antibody should be determined by the researcher.
Recombinant human ALK protein fragment corresponding to the cytoplasmic domain of the protein was used as the immunogen for the recombinant Anaplastic Lymphoma Kinase antibody.
Aliquot the recombinant Anaplastic Lymphoma Kinase antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.